Skip to main content

Media

Media Coverage on Recent Acquisition Announcement

Our recent transformative announcement was broadly covered in international media and industry publications highlighting the potential of our lead candidate CDR132L in heart failure and Cardior’s position as an RNA therapy pioneer for heart disease. We thank all reporters and media outlets who have shared our story.

Publications

Bild, Jana Kolbe

Milliarden-Deal für deutschen Piks gegen Herzschwäche

BioPharma Dive, Ned Pagliarulo

Novo to acquire heart failure drug in $1B deal for Cardior

BioSpace, Tristan Manalac

Novo’s $1.1B Cardior Buy Continues Expansion into Heart Disease

Bloomberg, Naome Kresge, Deidre Hipwell

Novo Nordisk Agrees to Buy Cardior for Up to €1 Billion

Handelsblatt, Maike Telgheder, Theresa Rauffmann

Novo Nordisk zahlt eine Milliarde für deutsches Biotech

Endpoints, Kyle LaHucik

Novo to buy mid-stage heart failure biotech Cardior for up to $1.1B

Financial Times, Ian Johnston

Novo Nordisk in €1bn deal for RNA-based heart disease therapies

Fierce Biotech, Nick Paul Taylor

Novo Nordisk inks $1B Cardior buyout to pump up heart failure

Handelsblatt, Maike Telgheder, Theresa Rauffmann

Cardior-Gründerin: „Wir sind seit Jahren auf der Watchlist von Big Pharma“

Scrip, Kevin Grogan

Novo Pumps Up Heart Failure Prospects With Cardior Purchase

Wall Street Journal, Dominic Chopping

Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Billion Purchase of Cardior Pharmaceuticals

WirtschaftsWoche, Andreas Menn

Wir haben das Potenzial, chronische Herzkrankheiten zu stoppen

Cardior Pharmaceuticals GmbH
Hollerithallee 20
30419 Hannover

Managing Director
Prof. Dr. Dr. Thomas Thum

Commercial Register
Registry Court: Hannover
HRB 214001
VAT ID: DE307067481

Email
info@cardior.de

Phone
+49 511 3385 9930

Contact us for career options
jobs@cardior.de

Visit us on
LinkedIn X

Made with ❤︎ by Eatch